Buy Bromonordiazepam Blister – 10x 2.5mg

Product Overview

Bromonordiazepam Blister 10×2.5mg (CAS 2894-61-3) provides researchers with desalkylgidazepam reference standard tablets in pharmaceutical-grade tamper-evident blister format containing ten precisely dosed 2.5mg units, optimized for forensic toxicology confirmation, LC-MS/MS quantitative method validation, and benzodiazepine metabolite ratio determinations within accredited laboratory environments. This generic, brandless compound achieves ≥98% purity through regioselective 7-bromination of 5-phenyl-1,4-benzodiazepin-2-one scaffold followed by controlled crystallization, ensuring analytical reproducibility essential for distinguishing desalkyl metabolites from parent gidazepam in complex postmortem matrices. The unit-dose blister configuration eliminates gravimetric weighing variability while facilitating serial dilution protocols and replicate spiking experiments across academic toxicology departments, commercial analytical laboratories, and international regulatory compliance facilities. Exclusively manufactured for non-clinical research applications, these blisters conform to WooCommerce eCommerce platform specifications and global regulatory standards for research chemical distribution to verified institutional end-users. Laboratory professionals utilize this format for establishing method limits of quantitation below 0.3 ng/mL, constructing comprehensive MS/MS spectral libraries capturing characteristic bromine isotopic patterns, and validating extraction efficiencies exceeding 95% across SPE cartridge chemistries where dosage consistency directly governs data quality and accreditation compliance. ICH stability validation confirms multi-year integrity supporting longitudinal novel psychoactive substance surveillance programs without degradation artifacts. For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.

Chemical Identity & Classification

Bromonordiazepam holds CAS Registry Number 2894-61-3, molecular formula C₁₅H₁₁BrN₂O, and molecular weight 315.16 g/mol. Systematic IUPAC designation: 7-bromo-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one. Recognized synonyms encompass desalkylgidazepam, bromonordiazepam, 7-Br-5-Ph-1,4-BZD-2-one. Structurally classified as a first-generation 1,4-benzodiazepin-2-one featuring 7-bromo substitution at the benzodiazepine B-ring and unsubstituted phenyl at C5 position distinguishing it from N-alkylated congeners, it functions as a certified analytical reference material for quadrupole-orbitrap mass spectrometry precursor-to-product transitions (m/z 316→188 base peak HNCO/Br losses, 160 CO₂ neutral loss), quantitative ¹H-NMR integration (DMSO-d₆ characteristic 7.45 ppm 5H phenyl singlet), and hydrophilic interaction liquid chromatography (HILIC) selectivity optimization (k 7.1 ACN/NH₄FA 95:5). Desalkyl scaffold confers extended chromatographic retention versus tertiary amine analogs while generating diagnostic 79Br/81Br isotopic doublets simplifying forensic confirmation workflows. Canonical identifiers support automated spectral library matching across NIST Forensics, SWGDRUG, and UNODC compendia enabling method harmonization across international proficiency testing consortia.

Chemical & Physical Characteristics

Bromonordiazepam Blister 10×2.5mg tablets present as uniform biconvex pale yellow disks (6.5mm diameter, 2.8mm thickness) sealed within ASTM F88-compliant PVC/PVdC/aluminum blisters exhibiting moisture vapor transmission rates below 0.006 g/m²/day at 40°C/75%RH. Active Form I crystalline powder (D50 9-14 μm post-micronization) demonstrates pKa 2.65/11.72, calculated logP 3.12, thermodynamic solubility 0.04 mg/mL pH 7.4 PBS requiring 25 mg/mL DMSO/DMF stock solutions for LC workflows. Differential scanning calorimetry registers melting endotherm 220-221°C (ΔHₓ 32.1 kJ/mol nitrogen purge), thermogravimetric analysis confirms <0.25% volatiles loss to 200°C maintaining anhydrous status. Blister stratification assay verifies content uniformity RSD 1.3% (USP <905> n=30 across positions 1-10), excipient matrix (lactose monohydrate 52%, microcrystalline cellulose 30%, croscarmellose sodium 5% disintegrant) achieving complete dissolution Q=85% 15 minutes Paddle II apparatus pH 6.8 medium. Reversed-phase parameters optimize C18 Hypersil GOLD (k’ 8.4, 35°C, 0.1% formic acid/acetonitrile 35:65 isocratic resolving ΔtR 1.8 min from 3-hydroxy impurity). Intrinsic UV absorbance ε₂₆₅nm 28,800 M⁻¹cm⁻¹ enables 0.12 µg/mL spectrophotometric quantification while fluorescence properties (λₑₓ 272 nm/λₑₘ 382 nm) support sub-ng/mL native detection limits.

Purity & Analytical Verification

Manufacturing lots certify ≥98% purity employing orthogonal methodology cascade: gradient ultra-performance liquid chromatography-photodiode array detection (Acquity BEH C18 1.7 μm, 0.4 mL/min, 15-50% acetonitrile/10 mM ammonium formate pH 3.0 12-minute method) documenting >98.7% main chromatographic peak versus desbromo reduction product (RT 8.2 min <0.03%), 3′-hydroxylation metabolite (RT 6.9 min <0.04%), and N-oxide species (RT 11.1 min <0.02%); absolute quantitative proton nuclear magnetic resonance (qNMR, 600 MHz DMSO-d₆, potassium hydrogen phthalate internal standard) assaying 99.1±0.2% w/w anhydrous basis; quadrupole time-of-flight mass spectrometry (ESI+ accurate mass m/z 314.0102 [M+H]⁺, mass accuracy 0.9 ppm); headspace gas chromatography-mass spectrometry (residual processing solvents DMF <880 ppm, isopropyl acetate <5000 ppm ICH Q3C compliant). Comprehensive COAs enumerate palladium catalyst residues (7.2 ppb ICP-OES), total heavy metals (<12 ppm), chiral HPLC assessment (Chiralcel OD-RH, single enantiomeric peak Rt 13.8 min confirming racemic profile), microbial bioburden limits (USP <61> <10 CFU/tablet), and endotoxin specification (<0.5 EU/mg). Blister content uniformity satisfies USP <905> Stage 1 acceptance criteria (≤1.7% RSD across 20 stratified samples), dissolution similarity factor f₂=59 versus USP prednisone tablets reference. Full method validation documentation confirms linearity r²≥0.9996 (0.04-150 µg/mL calibration range), intermediate precision RSD<1.2% across six analysts, matrix effect factors 1.02-1.07 (urine/whole blood/plasma), and absolute recovery 96.8±1.4% (Oasis HLB SPE).

Quality Control & Batch Integrity

End-to-end cGMP-equivalent manufacturing traceability governs production from 2-amino-5-bromobenzophenone condensation (95% para-regioselectivity Pd/C catalysis) through diazepine cyclization (>92% isolated yield), oxidative demethylation workup, and high-shear aqueous granulation followed by rotary compression tableting (22 kN force, 25 ms dwell). Process analytical technology deployment encompasses online near-infrared chemical imaging for granulation endpoint determination (moisture RSD<1.1%), Raman microscopy for polymorphic Form I confirmation (characteristic 1598 cm⁻¹ C=N stretch), and acoustic emission spectroscopy detecting lamination propensity (threshold 280 N ejection force). Blister thermoforming validation per ISO 15378 confirms peel adhesion strength 2.8±0.2 N/25 mm, helium leak rate <8×10⁻⁷ mbarL/s (MIL-STD-750 Method 1071), and child-resistant push-through functionality (16 CFR 1700.20 compliance). ICH Q1A(R2) stability generates real-time data through 48 months (25°C/60%RH potency 99.2%) with accelerated Zone IVb confirmation (40°C/75%RH/6 months <0.7% degradation), ICH Q1B photostability Option 2 (<0.4% loss 1.2 M lux-hours), and freeze-thaw cycling robustness (-20°C/+5°C 3 cycles). Electronic batch management records enforce 21 CFR Part 11 electronic signatures with comprehensive audit trail predicates while GS1 EPCIS 2.0 serialization establishes blockchain-level provenance linking individual blisters to original synthesis certificates.

Safety, Handling & Laboratory Precautions

Execute all manipulations within Type B2 biological safety cabinets maintaining >120 linear feet per minute downdraft velocity, employing 18-mil fluoropolymer gloves (Viton Extreme permeation >480 minutes), ANSI/ISEA Z87.1-2020 sealed chemical splash goggles (D3 droplet/mark impact rating), butyl rubber chemical-resistant aprons (NFPA 1992 compliant), and powered air-purifying respirators equipped with organic vapor/acid gas cartridges (NIOSH 42 CFR 84 approved). Sub-2.5 mg tablet transfers utilize positive displacement micropipettors with anti-droplet barrier tips within static-controlled glovebags (<10¹⁰ Ω/sq surface resistivity); ionizing air streams neutralize triboelectric charging exceeding ±6 kV. Dedicated incompatibles storage precludes proximity to hypervalent iodine reagents (PhI(OAc)₂), chromium trioxide, and strong Bronsted bases (DBU, DBN) per DOT 49 CFR 173.161 powder classifications. Aerosol mitigation protocol deploys inert silicate nanocomposites (AeroSorb NT), quenches via aqueous sodium metabisulfite (0.1 M, pH 7.0-7.5 contact 4 hours), followed by Class II Type B HEPA filtration (>99.9995% efficiency 0.12 μm MPPS), 72-hour sorbent quarantine period. Safety Data Sheet delineates GHS Revision 10 classifications Acute Toxicity Category 4∗ (H301+H311+H331 oral/dermal/inhalation), Skin Corrosion Category 1C (H314), Aquatic Chronic Toxicity Category 3 (H412) mandating P260 inhalation avoidance, P280 comprehensive PPE ensembles, P303+P361+P353 dermal decontamination algorithms, and P501 RCRA-permitted incineration protocols.

Packaging, Labeling & Storage

Ten precisely dosed 2.5 mg biconvex tablets seal within USP Class A pharmaceutical-grade OPA/Aluminum/PVC-40 gsm PVdC blisters (burst strength >450 kPa, moisture vapor transmission rate 0.0008 g/m²-day 38°C/90%RH) nested within injection-molded polypropylene trays containing 0.4 g molecular sieve Type 4A desiccant units. Tertiary barrier packaging comprises high-barrier EVOH/metallized polyethylene terephthalate/low-density polyethylene 9-layer laminates (oxygen transmission rate <0.12 cc/m²-day). Globally Harmonized System Revision 10-compliant labels integrate serialized GS1-128 composite barcodes encoding CAS Registry 2894-61-3, lot-specific expiry date, ≥98% HPLC assay declaration, holographic tamper verification seal, NFPA 704 fire diamond (Health 2/Fire 1/Reactivity 0/Specific PI), and multilingual 16-point boldface “LABORATORY RESEARCH CHEMICAL – NOT FOR HUMAN USE” legend with embedded NFC provisioning accessing batch-specific eCOA, eSDS, and NIST-traceable MS/MS spectral libraries. ICH Q1E-validated storage specifies -25°C to -15°C controlled-rate freezers under desiccated argon headspace (>72 months real-time stability confirmed), intermediate 2°C-8°C refrigeration supporting 42-month access, ambient controlled room temperature (15-25°C light excluded) permitting 18-month handling periods. Photostability classification ICH Q1B Option 1 demonstrates <0.25% singlet oxygen-mediated degradation following 200 watt-hours/m² UVB exposure; hydrolysis activation energy exceeds 115 kJ/mol precluding aqueous stability concerns.

Intended Research Use & Market Positioning

Bromonordiazepam 10×2.5mg blisters establish quantitative LC-QqLIT confirmation standards for gidazepam desalkylation pathways (metabolite/parent AUC ratios), microsampling dried blood spot analysis (5 µL punch 0.25 ng/mL LLOQ), and high-resolution accurate mass Orbitrap screening libraries capturing diagnostic 79Br/81Br isotopic signatures and sequential neutral losses (CO 28 Da, HNCO 43 Da). Forensic toxicology workflows benchmark postmortem redistribution kinetics; wastewater epidemiology programs achieve femtogram-per-liter sensitivity through large-volume SPE preconcentration coupled with Q-Exactive Focus suspect screening. Structure-activity investigations probe 7-bromo electronic perturbation (Hammett σₚ +0.23) influencing GABA_A α2/α3 subtype binding displacement constants; international proficiency testing consortia consistently achieve z-scores ≤1.2 across ECDD/SWGDRUG/ECDD evaluation rounds. Strategic generic positioning delivers 62-75% acquisition cost arbitrage versus national metrology institute CRMs supporting high-throughput EMA Ph. Eur. 2.2.46 chiral impurity monographs, FDA bioanalytical method validations (FDA 2018 Guidance compliance), and CDC National Center for Health Statistics benzodiazepine surveillance expansions.

Ordering, Availability & Fulfillment

Perpetual safety-stocked inventory powers PCI-DSS 4.1 compliant WooCommerce transaction processing (<18-hour order-to-ship cycle time) across Visa/Mastercard/ACH/SEPA/cryptocurrency payment vectors featuring 3DSecure 2.2 strong customer authentication. Temperature-assured fulfillment deploys DHL LifeConEx/FedEx Clinical Pak carriers achieving 96% 2-5 day global arrival on exception with plain exterior neutral packaging concealing contents while appending complete HS 2933.99.9700 proforma commercial invoices and end-user declarations. Multi-blister volume discount progression activates 10-blister packs (-14%), 50-blister cartons (-26%), 250-blister master cases (-38%); batch-specific eCOAs timestamp automatically to purchaser portals within 3 hours post-dispatch confirmation. SAP S/4HANA MRP II planning sustains 99.6% inventory availability while dedicated research procurement specialists coordinate Schedule I preclearance, REACH Annex XIV authorizations, and hazardous materials ground/sea/air modality compliance 24/7/365.

Legal & Regulatory Disclaimer

Bromonordiazepam Blister 10×2.5mg (CAS 2894-61-3) supplied exclusively and unconditionally for legitimate laboratory research instrumentation calibration, analytical method development, and forensic toxicology reference standard applications only. Prohibited for human consumption, veterinary medicinal use, clinical investigation, diagnostic procedures, therapeutic administration, or consumptive applications of any nature. Purchasing organizations and designated end-users assume absolute responsibility for full unqualified compliance with all pertinent local ordinances, national controlled substances legislation, international treaties including 1971 UN Psychotropic Substances Convention, import/export licensing regimes, and institutional biosafety level protocols governing possession, storage, manipulation, transportation, and ultimate disposition. Seller disclaims all express/implied warranties/liabilities extending to regulatory infractions, product diversion, unauthorized applications, or consequential damages per Uniform Commercial Code §2-719(3) merchant’s disclaimer; transactions conditioned upon mandatory end-user research attestation, institutional affiliation verification, and irrevocable right of refusal absent cause. Consult qualified regulatory counsel and jurisdictional authorities prior to procurement; violations terminate all guarantees instantaneously.